预约演示

Blackstone's $250M bet beats Xarelto in bleeding trial, making case for Anthos' ex-Novartis asset

2023-09-18

临床2期临床3期临床结果

Anthos Therapeutics has already moved abelacimab into three phase 3 clinical trials.

Anthos Therapeuticsences’ $250 millionabelacimab ex-Novartis drug candidate has racked up another phase 2 win. The data show Anthos Therapeutics’ abelacimab significantly cut bleeding compared to Bayer and Johnson & Johnson’s Xarelto, adding to evidence that the biotech's candidate can treat thrombosis without affecting hemostasis.

Blackstone Life Sciencesthe anti-Factor XI/XIa antibNovartisn known as MAA868, in a pair of phase 2 trials in 2018. The studiAnthos Therapeutics aabelacimabability of the molebleedinginhibit FXI iBayerial fJohnson & JohnsonntsXareltoevent clots in people undergoing knee replacement. However, thrombosisithdrew the trials before enrolling any patients, and the next year Blackstone swept in and licensed the asset.

Novartisen, Anthos, the biotanti-Factor XI/XIa antibodydvance the candiMAA868has generated evidence that Novartis may have let go of a winner. Anthos linked the antibody to an 80% reduction iFXIenouatrial fibrillationompared to enoxaparin in 2021 and has now followed up with data on bleeding.Novartis Blackstone

Existing druAnthosp venous thromBlackstone, the formation of blood clots in veins, but raise the risk of Novartis. Anthos sees abelacimab as a Anthos dissociate thrombosis from hemostasis, prevvenous thromboembolismausing as bigenoxaparinse in bruising and bleeding. The 1,287-subjectbleeding trial that read out on Monday provides more evidence to support that theory.

Afib patients at modvenous thromboembolismstroke received Xarelto or one of two doses of the investigatiobleedingboAnthosich waabelacimabered subcutaneously oncethrombosisThe clinical trial linked the drug candidate to a reduction in the rate obruisingor clbleeding relevant non-major bleeding events, prompting Anthos to stop the study and offer patients on Xarelto the chance to switch to abelacimab.

Anthos, which will keep tracking patients strokeextension Xareltois yet to share data from the phase 2 trial but called the reduction in bleeding “overwhelming” and “unprecedented.” The biotech will share the full data at an upcoming scientific congress.Anthos Xarelto abelacimab

Anthostatement, Brigham and Women’s Hospital's Marc Sabatine, M.D., called the trial “the largest and longest head-to-head study of a Facbleedingnhibitor to provide definitive evidence of a highly significant reduction in bleeding as compared to a standard-of-care anticoagulant.” The study had a median of 21 months of follow-up.

Anthos has alreaBrigham and Women’s Hospitalee phase 3 clinical trials that are enrolling people with afib and cancer patients at riskFactor XI inhibitormbolism. The biotech is one of a clutch of developers going after FXIbleedingristol Myers Squibb and J&J collaborating on milvexian and Bayer developing asundexian, both of which are given orally.

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。

机构